---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-300412"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:08:37.158630+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bioventus appoints Robert Claypoole as President and CEO effective Jan 10, 2024

## Summary
- Claypoole appointed President and CEO effective Jan 10, 2024, succeeding interim CEO Anthony Bihl.
- Compensation: $800k base, 100% bonus target, $750k sign-on cash, 375k RSUs and 850k options.
- Claypoole previously EVP at Mölnlycke Health Care, leading $1.2B wound care; also held senior roles at Medtronic and Covidien.
- Company reaffirms full year financial guidance previously announced on November 7, 2023.

## SEC filing metadata
- accession: 0001193125-23-300412
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/0001193125-23-300412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/d448507d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-300412
- JSON: https://secwatch.observer/filing/0001193125-23-300412.json
- Plain text: https://secwatch.observer/filing/0001193125-23-300412.txt

## Key facts
- Executive change
  Robert E. Claypoole was appointed as President and Chief Executive Officer at Bioventus Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: Robert E. Claypoole has been appointed as the Company’s President and Chief Executive Officer, and as a Class III director of the Company, effective January 10, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/0001193125-23-300412-index.htm
- Executive change
  Anthony P. Bihl III departed as Interim President and Chief Executive Officer at Bioventus Inc..
  - Action: succeeded
  - Role: Interim President and Chief Executive Officer
  source text: succeeding Anthony P. Bihl III, the Company’s current Interim President and Chief Executive Officer, in such roles.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/0001193125-23-300412-index.htm
- Executive change
  Robert E. Claypoole was appointed as Class III Director at Bioventus Inc..
  - Action: appointed
  - Role: Class III Director
  source text: and as a Class III director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/0001193125-23-300412-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.